Skip to main content
Fig. 2 | Radiation Oncology

Fig. 2

From: Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience

Fig. 2

a Overall survival for patients with mCRPC treated with (N = 40) and without (N = 109) cytoreductive radiotherapy. b Overall survival of patients treated with cytoreductive RT before abiraterone failure (AbiRT, N = 30), after abiraterone failure together with other secondary hormone therapies (cRT + non-Abi, N = 10) and no cytoreductive RT (non-cRT, N = 109)

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us